Cell & Gene Therapy Answers: The Evolving Cell & Gene Therapy Landscape

We recently sat down with Maryland Franklin, Vice President and Enterprise Head of Cell & Gene Therapy at Labcorp Drug Development, to discuss key considerations for developing cell or gene therapies in today’s quickly expanding pipeline.

A Successful Remote Monitoring Strategy for Clinical Studies

The COVID-19 pandemic forced study teams to adapt, improvise and overcome as they faced the need to monitor clinical trials, sites and patients from remote locations. Moving forward, we see remote monitoring as part of a successful strategy for managing clinical studies. In this posting, we share “lessons learned” and best practices.

Cell & Gene Therapy Answers: Addressing Complex Analytical Needs with ddPCR/qPCR

Your source for answers to the complex challenges of cell and gene therapy development.

Decentralized Clinical Trials (DCT) Monthly Blog – October 2021

This month in the blog, we are going to look at how new options within the U.S. for handling investigator oversight of clinical trials.

Expanded crop protection and chemical testing: For those committed to our planet’s sustainability and the welfare of humanity

We’ve been ramping up our product testing support at some of our European sites over the past few years to meet the needs of the rapidly growing crop protection and chemical industry. Now, we’re excited to announce a multimillion-dollar expansion at our Greenfield, Indiana campus in the U.S. that enhances your options even further to access more crop protection and chemical toxicology studies at a global scale.

Enhancing the Investigator Site Experience with Electronic Query Notification and Resolution (eQuery)

Investigator sites provide an essential connection between drug development sponsors and patients in clinical trials—and play a key role in producing high-quality data. To better support a site’s day-to-day study activities and make a difference for patient care, Labcorp Central Laboratory Services (CLS) is continually evaluating current practices and implementing ongoing process improvements.

Anti-Drug Antibody (ADA) positive controls generation against oligonucleotide therapeutics: Anti-Oligonucleotide antibody case study

Oligonucleotide therapeutics are generally single-stranded synthetic oligonucleotides with modifications in their structure to improve stability and PK properties. These therapeutics generally target RNA transcripts and reduce or modify the corresponding protein expression. Unlike most typical biologic drug classes such as monoclonal antibodies, the oligonucleotides are relatively small in size and contain fewer potential epitopes. In addition, the oligonucleotide therapeutics are delivered to immune restricted sites to remain locally confined.

Asia Pacific Expansion

4.7 billion. That’s the approximate population of Asia as of 2021. That number represents about 59 percent of the total world population. People are living longer and with that comes the demand for improved healthcare. With the Asia Pacific region accounting for about 15 percent of the drug development pipeline today, it’s no wonder that it is growing at a double-digit rate.

Connecting Expertise to Accelerate Lab Testing Innovations at Labcorp Central Laboratory Services

To help our clients shape the future of healthcare, Central Laboratory Services (CLS) at Labcorp Drug Development is continuously exploring new ways to enhance scientific expertise and anticipate lab testing needs.

Early development investments campaign magazine

Moving with urgency takes determination, ingenuity and passion. It also takes innovating where it matters most. The decision to invest more than $700 million in the past five years in Early Development all started with listening to you. These initiatives have spanned the entire globe with a mission to expand capacity, enhance technology and produce new ways of working to ensure you have the insight, speed and flexibility you need to advance your development programs and pursue answers to life-changing breakthroughs.